Sorrento Therapeutics 過去の業績

過去基準チェック /06

Sorrento Therapeuticsの収益は年間平均-27.1%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 5.2%割合で増加しています。

主要情報

-27.1%

収益成長率

6.3%

EPS成長率

Biotechs 業界の成長	11.5%
収益成長率	5.2%
株主資本利益率	n/a
ネット・マージン	-852.6%
前回の決算情報	30 Jun 2023

Recent updates

収支内訳

Sorrento Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

LSE:0L85 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
30 Jun 23	64	-548	194
31 Mar 23	61	-672	193
31 Dec 22	63	-573	182
30 Sep 22	60	-494	198
30 Jun 22	55	-524	196
31 Mar 22	57	-472	198
31 Dec 21	53	-428	197
30 Sep 21	51	-355	183
30 Jun 21	51	-320	159
31 Mar 21	47	-231	133
31 Dec 20	40	-298	116
30 Sep 20	42	-290	100
30 Jun 20	36	-270	101
31 Mar 20	33	-249	105
31 Dec 19	31	-292	104
30 Sep 19	25	-279	101
30 Jun 19	24	-262	96
31 Mar 19	21	-279	79
31 Dec 18	21	-204	64
30 Sep 18	35	-105	51
30 Jun 18	152	-60	42
31 Mar 18	153	0	39
31 Dec 17	152	9	38
30 Sep 17	135	-57	41
30 Jun 17	16	-39	36
31 Mar 17	12	-68	32
31 Dec 16	8	-61	24
30 Sep 16	5	-67	24
30 Jun 16	4	-83	24
31 Mar 16	5	-51	22
31 Dec 15	5	-46	22
30 Sep 15	4	-31	13
30 Jun 15	4	-38	10
31 Mar 15	4	-35	9
31 Dec 14	4	-35	10
30 Sep 14	3	-37	10
30 Jun 14	2	-33	9
31 Mar 14	1	-29	8
31 Dec 13	0	-22	6
30 Sep 13	0	-12	4
30 Jun 13	1	-10	4
31 Mar 13	1	-6	3

質の高い収益: 0L85は現在利益が出ていません。

利益率の向上: 0L85は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 0L85は利益が出ておらず、過去 5 年間で損失は年間27.1%の割合で増加しています。

成長の加速: 0L85の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 0L85は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: 0L85の負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Sorrento Therapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.33 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.36 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.009 (vs US$0.36 loss in 1Q 2020)

Full year 2020 earnings released: US$1.30 loss per share (vs US$2.20 loss in FY 2019)

Recent updates

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R Mzl)

Sorrento Therapeutics, Inc. Announces Full Enrollment of Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), Second Generation Oral Mpro Inhibitor, as Standalone Treatment for COVID-19

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from S&P Biotechnology Select Industry Index

Sorrento Therapeutics Received Written Notice from the Staff of The Nasdaq Stock Market LLC

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Sorrento Therapeutics, Inc. Releases Unblinded Phase 1B Study Data of Its Oral Main Viral Protease Inhibitor, OVYDSO™ (STI-1558) in Covid Patients

Sorrento Therapeutics Receives FDA Clearance to Initiate Clinical Trials with A Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Sorrento Therapeutics, Inc. Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress of the European Society for Medical Oncology (Esmo)

Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from A Phase IB Study in China with STI-1558

No longer forecast to breakeven

Less than half of directors are independent

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Sorrento Therapeutics, Inc. Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with Sti-1558, an Oral Mpro Inhibitor as A Standalone Oral Treatment and Prevention of Covid-19 Without the Need for A Ritonavir Booster

Sorrento Therapeutics, Inc. Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures At 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

Sorrento Therapeutics, Inc. Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer

Sorrento Therapeutics, Inc. Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc. Announces the Completion of the SAD Portion of the Phase 1 Study of Its Oral Main Viral Protease (Mpro) Inhibitor, the STI-1558

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

Sorrento Therapeutics, Inc. Announces First Subject Dosed in A Phase I Clinical Study of Sti-1558, an Oral Mpro Inhibitor as A Standalone Treatment and Prevention of Covid-19 Without Co-Administration of Ritonavir Booster

Less than half of directors are independent

Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

Sorrento Therapeutics, Inc. Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

Sorrento Therapeutics, Inc. Announces That It Has Received Clearance from the FDA for Its Investigational New Drug Application for Intravenous (Iv) Sti-9167

Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors

Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients with Severe Pneumonia Due to Covid-19

Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure

Sorrento Therapeutics, Inc. announced delayed annual 10-K filing

Sorrento Therapeutics, Inc Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) acquired an unknown majority stake in Zhengzhou Fortune Bioscience Co., Ltd..

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of Virex Health, Inc.

Sorrento Announces its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. Announces Covishield (STI-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346K) Variants of Sars-Cov-2

Sorrento Therapeutics, Inc. Announces Completion of Enrollment in US Phase 2 Clinical Trial for Covi-Drops and Achievement of Interim Analysis Threshold in the UK

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

Sorrento Therapeutics, Inc. Begins Enrollment in Phase 2 Trial of Resiniferatoxin for the Treatment of Pain Due to Knee Osteoarthritis (OA)

Sorrento Announces Publication of Series of Novel Sars-Cov-2 Main Protease (Mpro) Inhibitors for Potential Treatment of Covid-19 Patients Infected with Sars-Cov-2 Variants of Concern, Including Omicron

Insufficient new directors

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.33 loss in 3Q 2020)

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

Sorrento Therapeutics, Inc. Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

Sorrento Therapeutics, Inc. Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device

Sorrento Therapeutics, Inc. Publishes Positive Initial Results of Sofusa® Lymphatic Drug Delivery System in A Phase 1B Rheumatoid Arthritis Study Using Enbrel

Sorrento Announces its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

Sorrento Therapeutics, Inc. Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.36 loss in 2Q 2020)

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

Sorrento Therapeutics, Inc. Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from Russell 3000E Index

Sorrento Therapeutics, Inc. Receives Emergency Use Authorization Approval and Import License from COFEPRIS for COVI-STIX and Plans Product Launch with Initial Shipments in July

Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of Third Quarter of 2021

Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting

Sorrento Announces Positive Results from Its License Partner, Kelun, on A Phase I Study of Safety and Pharmacokinetics of A166, A Novel Her2 ADC for Advanced Her2 Positive Breast Cancers

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of ACEA Therapeutics, Inc. for approximately $550 million.

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients with Acute Respiratory Distress Syndrome

First quarter 2021 earnings released: EPS US$0.009 (vs US$0.36 loss in 1Q 2020)

Sorrento Therapeutics, Inc. Receives FDA Clearance to Proceed with Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma

Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate

過去基準チェック /06